Evidence map›Paper›PMID 31037448›Full record

Observational studyJournal of gastroenterology2019

Is the new potent acid-inhibitory drug vonoprazan effective for healing idiopathic peptic ulcers? A multicenter observational study in Akita Prefecture, Japan.

Kae Sugawara, Shigeto Koizumi, Yohei Horikawa, Nobuya Mimori, Tsuyotoshi Tsuji, Hajime Ishii, Shusei Fujimori, Kengo Onochi, Hiroyuki Watanabe, Katsunori Iijima

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Journal of gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Kae SugawaraDepartment of Gastroenterology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, Akita, 010-8543, Japan.
Shigeto KoizumiDepartment of Gastroenterology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, Akita, 010-8543, Japan.
Yohei HorikawaDepartment of Gastroenterology, Hiraka General Hospital, Yokote, Japan.
Nobuya MimoriDepartment of Gastroenterology, Hiraka General Hospital, Yokote, Japan.
Tsuyotoshi TsujiDepartment of Gastroenterology, Akita City Hospital, Akita, Japan.
Hajime IshiiDepartment of Gastroenterology, Akita City Hospital, Akita, Japan.
Shusei FujimoriDepartment of Gastroenterology, Yokote Municipal Hospital, Yokote, Japan.
Kengo OnochiDepartment of Gastroenterology, Omagari Kosei Medical Center, Daisen, Japan.
Hiroyuki WatanabeDepartment of Gastroenterology, Akita Kousei Medical Center, Akita, Japan.
Katsunori IijimaDepartment of Gastroenterology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, Akita, 010-8543, Japan. kiijima@med.akita-u.ac.jp.
Akita University · JPAkita University Hospital · JPHiraka General Hospital · JPAkita Industrial Technology Center · JPYokosuka Kyosai Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe incidence of peptic ulcers unrelated to H. pylori infection and non-steroidal anti-inflammatory drugs (NSAIDs), termed idiopathic peptic ulcers (IPUs), has increased worldwide. We recently reported that IPUs were refractory to proton pump inhibitor (PPI) treatment. Vonoprazan, which was recently developed in Japan, has shown a more potent acid-inhibitory effect than ordinary PPIs. In the present study, we compared the healing rates among peptic ulcers of different etiologies following treatment with vonoprazan.

methodA multicenter observational study was performed at six participating hospitals in Akita Prefecture, Japan. Consecutive patients who had endoscopically confirmed gastro-duodenal ulcers were enrolled between August 2016 and March 2018. For each patient, the Helicobacter pylori infection status and NSAID use, including aspirin, were checked, and 20 mg vonoprazan was administered for 6 weeks for duodenal ulcers and 8 weeks for gastric ulcers. The healing status was checked by endoscopy at the end of vonoprazan treatment. Patients were divided into four subgroups according to the H. pylori status and NSAID usage.

resultsThe proportion of IPUs was 18.2%. A total of 162 patients completed the study protocol. The healing rate of IPUs was marginally lower than that of simple H. pylori-associated ulcers (81.2% vs. 93.5%, P = 0.05). Similarly, the healing rate of NSAID-related ulcers, irrespective of concomitant H. pylori infection, was significantly lower than that of simple H. pylori-associated ulcers.

conclusionsSix- or 8-week vonoprazan treatment still seems to be insufficient for healing IPUs. Longer-term vonoprazan or another treatment option may be required to heal potentially refractory peptic ulcers.

Indexed as

AgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalCohort StudiesDuodenal UlcerEndoscopy, GastrointestinalFemaleHelicobacter InfectionsHelicobacter pyloriHumansJapanMaleMiddle AgedProspective StudiesProton Pump InhibitorsPyrroles1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineAnti-Inflammatory Agents, Non-SteroidalProton Pump InhibitorsPyrrolesSulfonamidesH. pyloriNon-steroidal anti-inflammatory drugsPeptic ulcersVonoprazan

Identifiers

PMID31037448
OpenAlexW2943687338

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.